PE
TGTX icon

Point72 Europe’s TG Therapeutics TGTX Stock Holding History

Point72 Europe’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.61M Buy
100,050
+14,186
+17% +$467K 0.18% 102
2025
Q2 		$3.09M Buy
+85,864
New +$3.2M 0.12% 118
2024
Q3 		– Sell
-160,769
Closed -$2.86M – 181
2024
Q2 		$2.86M Buy
+160,769
New +$2.57M 0.24% 107

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 Europe's TGTX Position: Q3 2025 in Review

Point72 Europe increased its TG Therapeutics (TGTX) stake by 17% in Q3 2025, buying an estimated $467K and bringing the position to 100,050 shares worth $3.61M. The position accounts for 0.18% of the portfolio, ranked #102.

Point72 Europe first reported a position in TGTX in Q2 2024 and has held it in 3 quarters since. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Point72 Europe held 100,050 shares of TG Therapeutics worth $3.61M as of Q3 2025.
  • Point72 Europe bought 14,186 TG Therapeutics shares in Q3 2025, an estimated $467K.
  • TG Therapeutics made up 0.18% of Point72 Europe's portfolio in Q3 2025, its #102 holding.
  • Point72 Europe first reported a position in TG Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.